Moderna reports surprise profit, sets out road map for RSV vaccine

(Reuters) -Moderna on Thursday reported a surprise fourth-quarter profit, helped by cost cutting and some deferred payments, and the vaccine maker set out a commercial roadmap for its experimental respiratory syncytial virus (RSV) shot. Moderna posted a profit of $217 million, or 55 cents a share, for the quarter. Moderna Chief Financial Officer James Mock in an interview said the company beat its own forecast because of unexpected deferred revenue of $600 million and cost savings of around $300 million created by the company's effort to adjust its manufacturing output last year.

Related Keywords

Germany ,New York ,United States ,Australia ,Bengaluru ,Karnataka ,India ,Massachusetts ,Cambridge ,Cambridgeshire ,United Kingdom ,Leroy Leo ,Patrick Wingrove ,Us Centers For Disease ,Pfizer ,Reuters ,Response Authority ,Drug Administration ,Eu Health Emergency ,Chief Financial Officer James Mock ,Wall Street ,Disease Control ,Bill Berkrot ,Moderna ,James Mock ,Respiratory Syncytial Virus ,Covid Vaccine ,Vaccine ,Covid ,